Clopidogrel Tablet, Film Coated
Product Images NDC 68084-752

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 68084-752). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by American Health Packaging, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Ahp0253601

Clopidogrel bisulfate 75 mg film-coated oral tablet. The round pink tablet is imprinted with "APO" on one side and "CL 75" on the reverse, indicating the 75 mg strength. Manufactured by American Health Packaging.*

FDA Label Image

Ahp0275225

Clopidogrel 300 mg oral film-coated tablet, pink, oblong, with imprint "APO" on one side and "CL 300" on the other side. This prescription drug is labeled by American Health Packaging.*

FDA Label Image

Figure 1

A forest plot chart illustrating the effect of co-administered proton pump inhibitors (PPIs) on the exposure to the active metabolite of Clopidogrel 75 mg. It shows the mean and 90% confidence intervals for active metabolite AUC changes relative to Clopidogrel administered alone for Dexlansoprazole 60 mg, Lansoprazole 30 mg, Pantoprazole 80 mg, and Omeprazole 80 mg.*

FDA Label Image

Figure2 (Figure 2)

This line graph displays cumulative event rates (%) for cardiovascular death, myocardial infarction, and stroke over 12 months of follow-up in the CURE study. It compares two groups: one receiving placebo plus aspirin and the other receiving clopidogrel plus aspirin. The graph shows lower event rates in the clopidogrel plus aspirin group, with significance indicated by a p-value of 0.00009.*

FDA Label Image

Figure3.jpg (Figure 3)

A forest plot figure showing hazard ratios comparing Clopidogrel versus placebo across patient baseline characteristics and concomitant medications/interventions for the CURE study. Subgroups include age, gender, race, elevated cardiac enzymes, diabetes, previous myocardial infarction, and previous stroke. The x-axis shows hazard ratios with confidence intervals ranging from 0.3 to 1.4, indicating relative favorability toward Clopidogrel or placebo across examined subgroups.*

FDA Label Image

Figure3b.jpg (Figure 3b)

A forest plot figure depicting hazard ratios with 95% confidence intervals for patient subgroups and concomitant medications in the CURE study. It compares outcomes for Clopidogrel versus placebo across various subgroups including Heparin/LMWH use, Aspirin dose (<100, 100-200, >200 mg), GPIIb/IIIa antagonist use, Beta-Blocker use, and Ace Inhibitor use. The plot visualizes which treatment favors Clopidogrel or placebo.*

FDA Label Image

Figure4 (Figure 4)

A line graph titled 'Cumulative Event Rates for Death in the COMMIT Study' showing percentage dead before first discharge over days since randomization (up to 28 days). Two curves compare death rates: Placebo with 1845 deaths (8.1%) and Clopidogrel with 1726 deaths (7.5%), indicating a 7% proportional risk reduction (p=0.03). All treated patients received aspirin.*

FDA Label Image

Figure5 (Figure 5)

A line graph titled 'Cumulative Event Rates for the Combined Endpoint Re-Infarction, Stroke or Death in the COMMIT Study' showing the percentage of patients with death, re-infarction, or stroke over 28 days. The graph compares two groups: placebo with 10.1% event rate and Clopidogrel with 9.2% event rate, indicating a 9% proportional risk reduction (p=0.002). The x-axis represents days since randomization (up to 28 days), and the y-axis shows the percentage with events before first discharge. A note states all treated patients received aspirin.*

FDA Label Image

Figure6.jpg (Figure 6)

A forest plot chart titled 'Effects of Adding Clopidogrel to Aspirin on the Combined Primary Endpoint across Baseline and Concomitant Medication Subgroups for the COMMIT Study.' It displays odds ratios with confidence intervals for various subgroups including gender, age, hours since onset, systolic blood pressure, heart rate, and fibrinolytic agent use, comparing clopidogrel versus placebo outcomes in a clinical study.*

FDA Label Image

Figure7.jpg (Figure 7)

A line graph titled 'Fatal or Non-Fatal Vascular Events in the CAPRIE Study' depicting cumulative event rates (%) over months of follow-up (0 to 36). Two lines compare aspirin and clopidogrel, showing event rate trends with a p-value of 0.045 indicating statistical comparison between treatments.*

FDA Label Image

Figure8.jpg (Figure 8)

A forest plot chart titled 'Hazard Ratio and 95% CI by Baseline Subgroups in the CAPRIE Study' comparing Clopidogrel and Aspirin across conditions stroke, MI, and PAD, showing hazard ratios with 95% confidence intervals and the number and percentage of events for each subgroup and overall.*

FDA Label Image

Structure

Chemical structure of Clopidogrel Bisulfate, showing the molecular framework including a thiophene ring, a chlorophenyl group, and a carboxylate ester moiety, along with the associated sulfuric acid (H2SO4) component.*

FDA Label Image

Image 01

Label for Clopidogrel Tablets, USP 75 mg film-coated oral tablets by American Health Packaging. The package contains 100 tablets (10 x 10), marked Rx Only. Includes dosage information, storage instructions, and warnings to keep out of reach of children with distributor details from American Health Packaging, Columbus, Ohio.*

FDA Label Image

Image 02

Label sheet featuring multiple identical labels for Clopidogrel Tablet USP 75 mg, film coated, oral dosage form. Each label shows the strength 75 mg prominently, with placeholders for lot number and expiry date. The labeler is American Health Packaging, Columbus, OH. A barcode is included on each label.*

FDA Label Image

Image 03

Label for Clopidogrel Tablets, USP 300 mg, film-coated oral tablets. The package contains 30 tablets and is labeled Rx Only. The label includes dosage and storage instructions, a barcode, and manufacturer details for American Health Packaging, Columbus, Ohio.*

FDA Label Image

Image 04

Labels for Clopidogrel 300 mg tablets, USP, film-coated. Each label displays the proprietary name Clopidogrel, strength of 300 mg, tablet dosage form, and placeholder lot and expiry information. The labeler is American Health Packaging, Columbus, Ohio. Barcodes and NDC information are also present.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.